NAFLD and NASH patients and animal models display enhanced expression of CYP2E1 and lipid peroxidation (Robertson et al., 2001), with increased localization to areas in the liver with oxidative stress injuries, leptinemia, reduced adiponectin levels and insulin resistance in NAFLD (Weltman et al., 1996, 1998). The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.